Investor relations.

Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer, GMP-licensed by Health Canada, producing MDMA capsules and natural psilocybin extract for regulated treatment programs. This page provides the official stock, filings, and disclosure channels for investors.

• Apr 02, 2026

  Optimi Completes First Commercial Shipment of GMP MDMA

  First commercial shipment of GMP-certified MDMA capsules departs Princeton facility for a regulated access program partner.

• Mar 14, 2026

  Optimi Reports Q2 2026 Financial Results

  Second quarter revenue growth driven by expanded GMP psilocybin shipments and DEL-amended product mix.

• Feb 11, 2026

  Health Canada Grants DEL Amendment for Expanded Psilocybin Analogs

  Dealer's Licence amendment permits manufacture and distribution of an expanded set of psilocybin analogs.

• Interim financial statements

  Q2 2026 Condensed Interim Financial Statements
  Mar 14, 2026
• Management's discussion & analysis

  Q2 2026 MD&A
  Mar 14, 2026
• Annual information form

  Annual Information Form (FY2025)
  Dec 20, 2025